A study on 113 GBC patients found c-MET overexpression in 39.8% and c-MET gene amplification in 18.3% of the case series; the authors found that c-MET gene amplification was associated with aggressive clinicopathological features and adverse prognosis [50], consistent with other studies that found that c-MET has a negative prognostic role, and in a case series of 35 invasive gallbladder cancers, c-MET was amplificated in 74% of patients [51]. The gene discussed is MET; the disease is gallbladder cancer.